ReviewViruses2019
Hepatitis E Virus Drug Development.
Review in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV-Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Mitochondrial and lipid metabolism rewiring during HEV infection.Cellular and molecular life sciences : CMLS · 2026Article
- Phosphoinositide kinase PIKfyve inhibitor apilimod blocks hepatitis E virus infection.eGastroenterology · 2026Article
- Update on Hepatitis E Virus Infection 2025: Insights From an International Symposium.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Can Adoptive Immunotherapy With Hepatitis E Virus (HEV)-Specific T Cells Address the Unmet Need in Refractory Chronic HEV Infection?Open forum infectious diseases · 2025Article
- A novelJHEP reports : innovation in hepatology · 2025Article
- Hepatitis E virus: from innate sensing to adaptive immune responses.Nature reviews. Gastroenterology & hepatology · 2024Review
- From discovery to treatment: tracing the path of hepatitis E virus.Virology journal · 2024Review
- Genetic determinants of host- and virus-derived insertions for hepatitis E virus replication.Nature communications · 2024Article
- Be Aware of the Dog: Tacrolimus Usage and Chronic Hepatitis E Virus Infections.Kidney international reports · 2024Article
- Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment.JHEP reports : innovation in hepatology · 2024Article
- Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions.Virologica Sinica · 2024Article
- A decade of liver organoids: Advances in disease modeling.Clinical and molecular hepatology · 2023Review
- Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.Archives of virology · 2023Article
- Review
- Treatment of Hepatitis E.Advances in experimental medicine and biology · 2023Article
- Two mutations in the ORF1 of genotype 1 hepatitis E virus enhance virus replication and may associate with fulminant hepatic failure.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- An RNA Interference/Adeno-Associated Virus Vector-Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus.Hepatology communications · 2022Article
- Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems.Cells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in immunocompromised patients. The current therapy options are limited to the unspecific antivirals Ribavirin (RBV) and pegylated Interferon-α (pegIFN-α). RBV leads to viral clearance in only 80% of patients treated, and is, similar to pegIFN-α, contraindicated in the major risk group of pregnant women, emphasizing the importance of new therapy options. In this review, we focus on the urgent need and current efforts in HEV drug development. We provide an overview of the current status of HEV antiviral research. Furthermore, we discuss strategies for drug development and the limitations of the approaches with respect to HEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.